As an alternative to standard gene transfer techniques for genetic manipulation, we have investigated the use of triple helix-forming oligonucleotides to target mutations to selected genes within mammalian cells. By treating monkey COS cells with oligonucleotides linked to psoralen, we have generated targeted mutations in a simian virus 40 (SV40) vector contained within the cells via intracellular triple helix formation. Oligonucleotide entry into the cells and sequence-specific triplex formation within the SV40 DNA deliver the psoralen to the targeted site. Photoactivation of the psoralen by long-wavelength UV light yields adducts and thereby mutations at that site. We engineered into the SV40 vector novel supF mutation reporter genes containing modified polypurine sites amenable to triplex formation. By comparing the abilities of a series of oligonucleotides to target these new sites, we show that targeted mutagenesis in vivo depends on the strength and specificity of the third-strand binding. Oligonucleotides with weak target site binding affinity or with only partial target site homology were ineffective at inducing mutations in the SV40 vectors within the COS cells. We also show that the targeted mutagenesis is dependent on the oligonucleotide concentration and is influenced by the timing of the oligonucleotide treatment and of the UV irradiation of the cells. Frequencies of intracellular targeted mutagenesis in the range of 1 to 2% were observed, depending upon the conditions of the experiment. DNA sequence analysis revealed that most of the mutations were T ⅐ A-to-A ⅐ T transversions precisely at the targeted psoralen intercalation site. Several deletions encompassing that site were also seen. The ability to target mutations to selected sites within mammalian cells by using modified triplex-forming oligonucleotides may provide a new research tool and may eventually lead to therapeutic applications.Oligonucleotides can bind to duplex DNA and form triple helices in a sequence-specific manner (2,3,5,12,25,39). Progress in elucidating the third-strand binding code has raised the possibility of developing nucleic acids as sequence-specific reagents for research and possibly clinical applications. Oligonucleotide-mediated triplex formation has been shown to prevent transcription factor binding to promoter sites and to block mRNA synthesis in vitro and in vivo (4,9,11,17,18,21,26,29,33,41). Such inhibition of expression, however, is transient, depending on the sustained presence of the oligonucleotides. It also depends on the stability of the triple helix, which can be disrupted by transcription initiated at nearby sites (37). To overcome these problems, methods to prolong oligonucleotide-duplex interactions using DNA intercalating or cross-linking agents have been explored in experiments to block transcription initiation or elongation (17,18,39,40).Instead of using triplex formation to transiently block gene expression, however, we reasoned that it would be advantageous to use triple helix formation to target m...